Australia Insulin Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Australia insulin delivery devices market size in 2026 is estimated at USD 738.92 million, growing from 2025 value of USD 722.45 million with 2031 projections showing USD 826.84 million, growing at 2.28% CAGR over 2026-2031. This report is Segmented by Device Type (Insulin Pumps, Insulin Pens, Insulin Syringes, and More), Component (Delivery Devices and Consumables), End-User (Hospitals & Clinics, Home-Care Settings, and Ambulatory Surgical Centres), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).

Australia Insulin Delivery Devices Market Trends and Insights

Rising Prevalence Of Diabetes In Australia

Official surveys show 6.6% of Australian adults live with diabetes, yet University of Sydney researchers estimate the real number is 35% higher, lifting the patient pool above 2 million. The gap stems from under-registration in the NDSS, indicating latent demand that comes into the commercial funnel as detection improves. Urban clusters match the supplier network of major pump distributors, easing after-sales support. Earlier onset among younger cohorts extends lifetime therapy duration, which heightens interest in tech-forward pumps, pens, and connected wearables that fit digital lifestyles.

Expansion Of NDSS & Private Insurance Subsidies For Pumps

Since March 2025 the NDSS has subsidised Dexcom G7 and, from April 2025, Abbott FreeStyle Libre 2 Plus sensors, lowering out-of-pocket costs for hybrid closed-loop therapy. Private insurers follow suit: Insulet’s OmnipodPromise covers waiting periods so members can transition immediately to Omnipod 5. Medtronic runs “Bridging the Gap,” supplying MiniMed 780G during insurance onboarding. Combined public-private funding dismantles cost barriers for roughly 18,000 Australians judged clinically eligible for automated insulin delivery systems.

High Upfront & Consumable Costs Of Advanced Devices

Even after NDSS discounts, annual consumable spend for a pump user - infusion sets, reservoirs, sensors - can exceed USD 1,000, a notable outlay for middle-income households. Supply interruptions, such as the April 2024 withdrawal of particular Medtronic infusion sets, intensify cost by forcing brand switches or emergency purchases. Insurance coverage varies: some funds now cap Ozempic rebates and tightly manage device benefits, creating postcode-dependent access.

Other drivers and restraints analyzed in the detailed report include:

• Integration Of CGM-Enabled Closed-Loop Systems
• Ageing & Obesity-Driven Demand Growth
• Rapid Uptake Of GLP-1 Weight-Loss Drugs Reducing Insulin Demand

Segment Analysis

Insulin pumps captured a 46.10% slice of the Australia insulin delivery devices market in 2025, a dominance rooted in proven glycaemic benefits and expanding reimbursement. MiniMed 780G users achieve superior time-in-range, reinforcing trust in tubed pumps. Yet patch pumps are the growth engine, set for a 5.39% CAGR through 2031 as Omnipod 5 and emerging tubeless rivals lower insertion anxiety and simplify wear. As a result, patch platforms are poised to lift their share of the Australia insulin delivery devices market size for type 1 cohorts between 2026 and 2031.

Smart pens remain essential for cost-sensitive type 2 patients. NovoPen 6 and similar devices log doses automatically, supporting tele-review without adding pump-level expense. Syringes and jet injectors continue a slow decline because consumers migrate toward simpler, connected options. Embecta’s coming patch pump for type 2 users and Sequel’s modular twiist system hint at a bifurcated future: premium closed-loops for intensive users and pared-down wearables for the broader population.

Hardware generated 63.05% of revenue in 2025, underpinned by multi-thousand-dollar pump placements that anchor therapy for 4-5 years. Consumables follow a razor-and-blade model and post the steeper 5.62% CAGR as every pump user consumes infusion sets every 2-3 days and CGM sensors every 10 days. Because each active user represents annuity-style revenue, boosting the installed base enlarges lifetime value even if hardware ASPs flatten.

Supply security is critical. The April 2024 exit of certain Medtronic infusion sets highlighted vulnerability and encouraged wider stocking of alternate brands through NDSS logistics. Extended-wear sets now promise up to 7 days use, improving convenience but also trimming raw unit volumes. Nonetheless, sensor adoption attached to pumps is rising rapidly enough to sustain consumables momentum, cementing half of future Australia insulin delivery devices market size growth in recurring supplies.

Complete Report Scope:

• By Device Type
  • Insulin Pumps
    • Patch Pumps
    • Traditional Pumps
  • Insulin Pens
    • Reusable Pens
    • Disposable Pens
  • Insulin Syringes
  • Insulin Jet Injectors
  • Smart Insulin Delivery Wearables
• By Component
  • Delivery Devices
  • Consumables (Reservoirs, Cartridges, Infusion Sets, Needles)
• By End-User
  • Hospitals & Clinics
  • Home-care Settings
  • Ambulatory Surgical Centres
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

List of Companies Covered in this Report:

• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Medtronic
• Insulet
• Ypsomed
• Beckton Dickinson
• Roche
• Tandem Diabetes Care
• Embecta
• Terumo
• MannKind
• Biocon
• Julphar
• Dexcom (Smart Pens & CGM integration)
• Cellnovo
• SOOIL Development
• Terumo
• Nipro

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support